Noven Announces Availability of Briefing Documents for Daytrana(TM) Advisory Committee Meeting
Posted on: Thursday, 1 December 2005, 09:00 CST
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) confirmed today that the U.S. Food and Drug Administration (FDA) has posted briefing documents on its website - http://www.fda.gov - for the Psychopharmacologic Drugs Advisory Committee meeting to be held December 2, 2005 relating to Daytrana(TM) (methylphenidate transdermal system).
Daytrana(TM), licensed globally to Shire Pharmaceuticals Group plc, is an investigational transdermal patch designed for once-daily use to treat attention deficit hyperactivity disorder (ADHD) in children aged 6 to 12 years.
Documents posted on the FDA website include materials submitted by Noven and Shire as well as FDA materials.
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's prescription patches are sold in over 30 countries, and a range of new patches are being developed in collaboration with Shire Pharmaceuticals Group plc, Novartis Pharma AG, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others. See http://www.noven.com for additional information.
Source: Business Wire
Related Articles
- BioSante Pharmaceuticals Announces FDA Clarity on Development of LibiGel(R) (Transdermal Testosterone Gel) in the Treatment of Female Sexual Dysfunction
- Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (Lisdexamfetamine Dimesylate) As a Novel Treatment for ADHD
- FDA Approves Shire Colitis Treatment
- BioSante Pharmaceuticals Receives FDA Approval of Bio-E-Gel(R) (Estradiol Gel), to Be Marketed As Elestrin(TM)
- BioSante Pharmaceuticals Announces FDA Filing and Review of NDA for Bio-E-Gel(R)
- King Pharmaceuticals Reports FDA Acceptance of Altace(R) Supplemental New Drug Application for Delaying the Progression of Chronic Kidney Disease in Hypertensive, Non-Diabetic Patients
- Anadys Pharmaceuticals Announces FDA Acceptance of IND Application for ANA975
- Ligand Pharmaceuticals Receives FDA Request for AVINZA(R) Label Changes to Strengthen Warnings About Alcohol Consumption While Using AVINZA
- Amylin Pharmaceuticals Announces FDA Approval of SYMLIN(R) for Insulin-Using Type 2 and Type 1 Diabetes
- Manhattan Pharmaceuticals Granted FDA Approval to Initiate Phase I Clinical Trials for Oleoyl Estrone; Phase I Trial Expected to Begin in First Quarter 2005
 |
 |
User Comments (0)
RSS Feeds